Evidence map›Paper›PMID 33564419›Full record

ArticleClinical kidney journal2021

Recurrent acute interstitial nephritis: what lies beneath.

Fernando Caravaca-Fontán, Amir Shabaka, Beatriz Sánchez-Álamo, Alberto de Lorenzo, Martha Díaz, Miquel Blasco, Eva Rodríguez, Milagros Sierra-Carpio, Tamara Malek Marín, Andrés Urrestarazú and 4 more

Open access · goldAbstract read
In one paragraph

Article in Clinical kidney journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 2 countries.

Fernando Caravaca-FontánDepartment of Nephrology, Instituto de Investigación, Hospital Universitario 12 de Octubre, Madrid, Spain.ORCID 0000-0002-5830-9663
Amir ShabakaDepartment of Nephrology, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain.
Beatriz Sánchez-ÁlamoDepartment of Nephrology, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain.
Alberto de LorenzoDepartment of Nephrology, Hospital Universitario de Getafe, Getafe, Madrid, Spain.
Martha DíazDepartment of Nephrology, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Miquel BlascoDepartment of Nephrology, Hospital Clínic Barcelona, Universitat de Barcelona, Barcelona, Spain.
Eva RodríguezDepartment of Nephrology, Hospital del Mar, Barcelona, Spain.
Milagros Sierra-CarpioDepartment of Nephrology, Hospital San Pedro, Logroño, Spain.
Tamara Malek MarínDepartment of Nephrology, Hospital de Sagunto, Sagunto, Spain.
Andrés UrrestarazúDepartment of Nephrology, Hospital de Clínicas, Montevideo, Uruguay.
Clara Corona CasesDepartment of Nephrology, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain.
Manuel PragaDepartment of Nephrology, Instituto de Investigación, Hospital Universitario 12 de Octubre, Madrid, Spain.
Gema Fernández-JuárezDepartment of Nephrology, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain.
Spanish Group for the Study of Glomerular Diseases (GLOSEN)
Hospital Universitario Fundación Alcorcón · ESUniversidad Complutense de Madrid · ESHospital de Clínicas · UYHospital Del Mar · ESHospital de Sagunto · ESHospital San Pedro · ESHospital Universitario de Getafe · ESHospital Universitario Ramón y Cajal · ESUniversitat de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcute interstitial nephritis (AIN) is an emerging cause of acute kidney disease. While this disease usually follows an acute course, it may occasionally recur, representing a major challenge for the clinician.

methodsWe performed a retrospective, observational cohort study in 13 nephrology departments belonging to the Spanish Group for the Study of Glomerular Diseases. Patients with biopsy-proven AIN between 1996 and 2018 were included.

resultsThe study group consisted of 205 patients with AIN, 22 of which developed recurrent AIN (RAIN) after a median of 111 days from diagnosis. RAIN was due to a surreptitious reintroduction of a previously known implicated drug or toxic in six patients (27%), sarcoidosis in two (9%), Sjögren's syndrome in three (14%), light-chain-mediated AIN in two (9%) and tubulointerstitial nephritis and uveitis syndrome in two (9%), while in the rest of cases (32%), no precise cause could be identified. Microscopic haematuria was more frequent in patients with underlying systemic diseases. The first RAIN episode was treated with a repeated course of corticosteroids in 21 patients (95%). In six cases (27%), azathioprine and mycophenolate mofetil were added as corticosteroid-sparing agents. During a median follow-up of 30 months, 50 patients (27%) with no recurrences and 12 patients (55%) with RAIN reached Stages 4 and 5 chronic kidney disease (CKD). By multivariable logistic regression analysis, RAIN was independently associated with the risk of reaching Stages 4 and 5 CKD, even after adjusting for potential covariables.

conclusionsRAIN is infrequent but is associated with poor kidney survival. RAIN should prompt clinicians to search for an underlying aetiology other than drug induced. However, in a large percentage of cases, no precise cause can be identified.

Indexed as

acute interstitial nephritischronic kidney diseaserecurrent acute interstitial nephritis

Identifiers

PMID33564419
PMCPMC7857806
OpenAlexW3010783240

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.